Australia develops world-first treatment to avoid amputation

Australian researchers said yesterday that
with a world-first new treatment,many smokers and people with diabetes could avoid amputationsThe researchers saidthey found that if a patient deuatedthe lower extremities due toof blood vessels,pumping blood into the lower extremitieswith high pressure,can act as an activation to prompt new blood vessels in the legThe world's first patient to receive a new treatment has also saved a legLane, an vascular surgeon who developed the new treatment, says this is a major advance in medicineIn Western countries, about 340,000 patients a year have to undergo amputationsdue to peripheral vasculardiseases, and with this new treatment, such patients can avoid amputation Researchers have conducted a clinical trial in which the first patient to receive the new treatment is 52-year-old Australian man Brown Three surgeons had thought Brown needed an amputation, but the researchers used the new treatment to save him a leg Mr Lane said there was a clot in the blood vesselnext to Mr Brown's knee, causing a leg to suffer from a severe blood supply that caused him to lose consciousness and gradually become cold and white, and later the leg muscles began to necrosis, with ulcers and gangrene in the feet and toes Brown offered to participate in a clinical trial of the new treatment, so the researchers implanted a device in the femoral artery in his thigh , connected to an in vitro blood pump With the help of a high-pressure blood pump, the dying leg is fed another blood supply, and blood flow increases by 250 % , stimulating the growth of new blood vessels After a five-day, 50-hour pumping session, Brown's feet gradually warmed , blood, consciousness improved significantly, and ulcered feet and toes slowly healed, Lane said Experts say activating Brown's own blood vessels has prompted him to restore blood supplies to his lower limbs to avoid amputations Brown is still able to walk on his own legs after a year of treatment Roger, an associate professor in the Department of Bioengineering at the University of Sydney, said he hoped a series of clinical trials would be completed by the end of the year to make new therapies available (Ink)